Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

One-time IV penicillin added to standard penicillin for adults with acute tonsillitis, tonsillitis with peritonsillar phlegmon, or peritonsillar abscess

Official title: A Single Dose of Intravenous Penicillin as an Adjunct to Oral Penicillin in the Treatment of Acute Tonsillitis, Peritonsillar Phlegmon, and Peritonsillar Abscess - A Randomized, Double-Blind, Placebo-Controlled Trial

Run by Aarhus University Hospital · NCT07896226 · Data updated 2026-11-12

A single dose of intravenous benzylpenicillin is given alongside standard oral penicillin to adults with acute tonsillitis, peritonsillar phlegmon, or peritonsillar abscess to see if symptoms improve.

More Tonsillitis trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment154 (estimated)
SponsorAarhus University Hospital
Academic / other
Locations1 site (Aarhus, Central Jutland)
StatusRecruiting
StartedNovember 2026
Main results expectedDecember 31, 2028
Study endsDecember 31, 2029
Registry record updatedNovember 4, 2026
Trial IDNCT07896226 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with clinically verified AT, PP, or PTA treated by incision, without penicillin allergy.

Probably not a fit

Patients with penicillin allergy or those in whom the infection does not respond to penicillin may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4 trial tests whether adding a single IV dose of benzylpenicillin to usual oral phenoxymethylpenicillin improves outcomes for adults with AT, PP, or PTA treated by incision. Participants receive either the IV antibiotic or a placebo alongside standard care, with measurements focused on pain, symptom burden, analgesic use, complications, and long-term results. The study targets adults without penicillin allergy and seeks to understand if the adjunct reduces treatment failure or progression. The design reflects a pragmatic approach to real-world treatment settings in Denmark. Safety monitoring and ethical considerations are integral components of the protocol.

Why it matters

Potential benefit: If successful, patients may experience faster relief of symptoms and fewer complications.

How similar studies have gone: Previous work by the research group suggests beta-lactam antibiotics are effective, and this trial extends that approach to an adjunct IV dose; the outcome is not yet proven.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Participants must meet one of the following clinical criteria:

* Clinically verified acute tonsillitis (AT) with a Centor score of 3-4 and without peritonsillar phlegmon (AT group);
* Clinical acute tonsillitis (AT) with a Centor score of 3-4 and with peritonsillar phlegmon (PP group); or
* Peritonsillar abscess treated by incision (PTA group).

Additionally, participants must meet the following criteria:

* Written informed consent;
* Age ≥18 years.

Exclusion Criteria:

* Known allergy or hypersensitivity to penicillin;
* Pregnancy or planned pregnancy;
* Suspected or confirmed spread of infection, including but not limited to:
* Parapharyngeal or retropharyngeal abscess
* Necrotizing fasciitis
* Mediastinitis
* Lemierre's syndrome.

Where it's running

  • Aarhus University Hospital
    Aarhus, Central Jutland, Denmark
    Recruiting

Study contacts

  • Principal investigator: Tejs E Klug, MD, DMSc — Aarhus University Hospital

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.